The knockout of NLGN3 (an NGS gene) can decrease the invasion of glioma in vivo in mouse models (Venkatesh et al., 2015), supporting that NGS genes can be therapeutic targets. This evidence concerns the gene NLGN3 and central nervous system cancer.